Last deal

$112.M

Amount

Series B

Stage

13.02.2024

Date

4

all rounds

$247.M

Total amount

General

About Company
ProfoundBio is an oncology biotherapeutics company that develops novel antibody-based therapeutics for cancer patients.

Industry

Sector :

Subsector :

founded date

01.01.2018

Last funding type

Series B

IPO status

Private

Description

ProfoundBio is a clinical stage biotherapeutics company that aims to provide better treatment options for cancer patients. Their targeted therapeutics are designed to harness the power of the immune system to fight cancer and potentially provide a cure. With a focus on antibody-based therapeutics, ProfoundBio is at the forefront of developing innovative treatments for oncology patients.
Contacts